iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/27908543/
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb;76(2):290-298.
doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28.

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

April W Armstrong  1 , Michael P Siegel  2 , Jerry Bagel  3 , Erin E Boh  4 , Megan Buell  2 , Kevin D Cooper  5 , Kristina Callis Duffin  6 , Lawrence F Eichenfield  7 , Amit Garg  8 , Joel M Gelfand  9 , Alice B Gottlieb  10 , John Y M Koo  11 , Neil J Korman  5 , Gerald G Krueger  6 , Mark G Lebwohl  12 , Craig L Leonardi  13 , Arthur M Mandelin  14 , M Alan Menter  15 , Joseph F Merola  16 , David M Pariser  17 , Ronald B Prussick  18 , Caitriona Ryan  15 , Kara N Shah  19 , Jeffrey M Weinberg  12 , MaryJane O U Williams  20 , Jashin J Wu  21 , Paul S Yamauchi  22 , Abby S Van Voorhees  23
Affiliations
Free article
Review

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

April W Armstrong et al. J Am Acad Dermatol. 2017 Feb.
Free article

Abstract

Background: An urgent need exists in the United States to establish treatment goals in psoriasis.

Objective: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice.

Methods: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds.

Results: A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less.

Limitations: Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects.

Conclusion: With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.

Keywords: Physician Global Assessment; biologics; body surface area; outcome measures; psoriasis; systemic therapies; treat to target; treatment; treatment goals.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles